Q-omics provides the consensus-scored NBPF15 profile across patient tissues and cancer cell-line models. NBPF15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NBPF15 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NBPF15 RNA expression shows 20,799 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where NBPF15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF15 survival associations across molecular data types. NBPF15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF15 RNA expression–survival associations across cancer types. High NBPF15 expression shows unfavorable associations in ACC, KICH, LIHC, CESC and LGG, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NBPF15 RNA expression.
This table summarizes NBPF15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF15 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, HNSC, COAD and BLCA. The KIRC box plot shows higher NBPF15 RNA expression in tumor versus normal tissue (log2 FC = +1.014, t-test p < 0.001).
This table shows molecular features associated with NBPF15 in patient tissues and cancer cell lines. In patient samples, NBPF15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
